New pill targets advanced cancers in early human trial

NCT ID NCT05585320

Summary

This early-stage study is testing a new oral medication called IMM-1-104 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, melanoma, and lung cancer. The drug is being tested alone and in combination with other approved treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Cancer Institute

    Durham, North Carolina, 27710, United States

  • Florida Cancer Specialists and Research Institute

    Lake Mary, Florida, 32746, United States

  • Hematology Oncology Associates of Central New York

    East Syracuse, New York, 13057, United States

  • Levine Cancer Center

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • NEXT Oncology

    Fairfax, Virginia, 22031, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 27203, United States

  • Sarah Cannon Research Institute

    Denver, Colorado, 80218, United States

  • Sarcoma Oncology Center

    Santa Monica, California, 90403, United States

  • University of California San Diego

    San Diego, California, 92037, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Wisconsin Clinical Science Center

    Madison, Wisconsin, 53792, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.